Endologix, a privately held global medical device company focused on advancing innovative therapies for the interventional treatment of vascular disease, announced the acquisition of the Pounce Thrombectomy System from Surmodics.
The Pounce System is an FDA-cleared, fully mechanical thrombectomy system designed for the non-surgical removal of thrombi and emboli from peripheral arteries. Built around proprietary dual-basket technology and a nitinol collection funnel, the system is intended to support procedural simplicity, versatility, and efficiency without requiring capital equipment, thrombolytics, or aspiration. The platform includes multiple commercially available configurations, including Pounce LP, Pounce, and Pounce XL, supporting a range of peripheral arterial vessel sizes, including smaller and more distal vessels. The Pounce Thrombectomy System will continue to be marketed under its existing FDA clearance during a transition period following the acquisition.
The acquisition expands Endologix’s commercial offering for vascular interventionalists already using the company’s DETOUR, ALTO, and AFX2 platforms. By adding a mechanical thrombectomy solution, Endologix aims to support a broader continuum of care for patients with peripheral vascular disease. As part of the transaction, a core group of Surmodics team members supporting the Pounce platform will join Endologix.
KEY QUOTES:
“The Pounce Thrombectomy System is a strong strategic and clinical fit for Endologix. It serves the same physicians and patients we already work with every day and brings a clinically differentiated mechanical approach that complements our vascular intervention portfolio. We are excited to welcome members of the Pounce team as part of our intentional investment in innovation that helps vascular specialists deliver better care.”
John Liddicoat, M.D., President and Chief Executive Officer, Endologix
“I have used both Pounce and Endologix technologies in my practice, and bringing these solutions together under one organization makes a great deal of clinical sense. The Pounce fully mechanical thrombectomy system offers a grab-and-go solution that does not rely on thrombolytics or aspiration and complements Endologix’s portfolio of vascular technologies for the treatment of peripheral arterial disease. Together, these technologies provide physicians with additional flexibility when addressing thrombi and emboli in the peripheral arterial vasculature.”
Venkatesh Ramaiah, M.D., FACS, Chief of Vascular and Endovascular Surgery, Pulse Cardiovascular Institute
